[SCHEDULE 13G/A] Quantum Biopharma Ltd. Class B Subordinate Voting Shares SEC Filing

Rhea-AI Filing Summary

Malone Wealth Ventures LLC reports beneficial ownership of 1,047,155 common shares of Quantum Biopharma Ltd., equal to 27.4% of the class. The filer discloses sole voting power for 104,289 shares and sole dispositive power for 1,047,155 shares. The filing is made on Schedule 13G (Amendment No. 7) indicating a passive reporting status and states that shares were acquired and are held in the ordinary course of business, not to influence control. The filing lists U.S. addresses for Malone Wealth Ventures LLC and the issuer’s Toronto executive office.

Positive

• Material disclosure of 27.4% beneficial ownership provides clear transparency to the market.
• Schedule 13G filing indicates the stake is reported as passive, with certification that holdings are not for changing control.
• Detailed ownership breakdown is provided: 1,047,155 shares beneficially owned, 104,289 sole voting power, 1,047,155 sole dispositive power.

Negative

• None.

Insights

Financial Analyst

TL;DR: Malone Wealth holds a material 27.4% stake in QNTM reported on Schedule 13G, indicating significant passive ownership without intent to influence control.

The filing discloses 1,047,155 shares beneficially owned with sole dispositive power and limited sole voting power of 104,289 shares. Because this is a Schedule 13G (passive), the filer certifies holdings are ordinary-course and not for changing control. The stake size is material for investors seeking ownership concentration data and for shareholder voting dynamics, but the filer affirms no control purpose.

Corporate Governance Expert

TL;DR: A single reporting entity now holds over 25% of the class, which is material to governance despite the passive Schedule 13G classification.

The form shows Malone Wealth Ventures LLC as an IA type reporting person with a comment recorded as "Les Gro." The document explicitly states clients have rights to dividends or proceeds but no known individual client exceeds 5% separately. The filing date references an event date of 06/11/2025 and is signed on 09/04/2025. This disclosure informs the shareholder registry and may affect quorum and major vote outcomes given concentration.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 7)

Quantum Biopharma Ltd.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

74764Y205

(CUSIP Number)

06/11/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 74764Y205

1

Names of Reporting Persons

Malone Wealth Ventures LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 104,289.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,047,155.00
8	Shared Dispositive Power

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,047,155.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

27.4 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: Les Gro

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Quantum Biopharma Ltd.
(b)	Address of issuer's principal executive offices: 55 UNIVERSITY AVENUE, SUITE 1003, 55 UNIVERSITY AVENUE, SUITE 1003, TORONTO, ONTARIO, CANADA, M5J 2H7.
Item 2.
(a)	Name of person filing: Malone Wealth Ventures LLC
(b)	Address or principal business office or, if none, residence: 9201 W State St. Ste 126 Boise, ID 83714
(c)	Citizenship: United States
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 74764Y205
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1047155
(b)	Percent of class: 27.4 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 104289
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1047155
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Clients of Malone Wealth Ventures LLC have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, the securities reported herein. No individual client is known to have such interest relating to more than five percent of the class.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Malone Wealth Ventures LLC

Signature:	Kevin M Malone
Name/Title:	President & CEO
Date:	09/04/2025

FAQ

How many Quantum Biopharma Ltd. (QNTM) shares does Malone Wealth Ventures LLC report owning?

The filing reports 1,047,155 shares beneficially owned.

What percentage of QNTM does Malone Wealth Ventures LLC own?

Malone Wealth reports owning 27.4% of the class.

Does the Schedule 13G indicate Malone Wealth intends to influence control of QNTM?

No. The filing is on Schedule 13G and includes a certification that holdings were not acquired and are not held to change or influence control.

How many shares does Malone Wealth have sole voting power over in QNTM?

The filer reports sole voting power for 104,289 shares.

When are the event and signature dates noted in the filing?

The date of event requiring filing is 06/11/2025 and the signature date is 09/04/2025.